Broker-Dealer AgreementBroker-Dealer Agreement • September 3rd, 2020 • Global Cancer Technology, Inc. • Surgical & medical instruments & apparatus
This agreement (together with exhibits and schedules, the “Agreement”) is entered into by and between Global Cancer Technology, Inc. (“Client”), a Delaware Corporation, and Dalmore Group, LLC., a New York Limited Liability Company (“Dalmore”). Client and Dalmore agree to be bound by the terms of this Agreement, effective as of July 15, 2020 (the “Effective Date”):
SUBSCRIPTION AGREEMENTSubscription Agreement • September 8th, 2020 • Global Cancer Technology, Inc. • Surgical & medical instruments & apparatus • Nevada
THIS INVESTMENT INVOLVES A HIGH DEGREE OF RISK. THIS INVESTMENT IS SUITABLE ONLY FOR PERSONS WHO CAN BEAR THE ECONOMIC RISK FOR AN INDEFINITE PERIOD OF TIME AND WHO CAN AFFORD TO LOSE THEIR ENTIRE INVESTMENT. FURTHERMORE, INVESTORS MUST UNDERSTAND THAT SUCH INVESTMENT IS ILLIQUID AND IS EXPECTED TO CONTINUE TO BE ILLIQUID FOR AN INDEFINITE PERIOD OF TIME. NO PUBLIC MARKET EXISTS FOR THE SECURITIES, AND NO PUBLIC MARKET MAY DEVELOP FOLLOWING THIS OFFERING.
Manhattan Street Capital Reg A+ Engagement AgreementEngagement Agreement • July 13th, 2021 • Global Cancer Technology, Inc. • Surgical & medical instruments & apparatus
This agreement (this "Agreement") will confirm the arrangements under which FundAthena, Inc., DBA Manhattan Street Capital ("MSC") and Global Cancer Technology, a Nevada Corporation/LLC, and its present and future subsidiaries and any entity used thereby to facilitate the Financings contemplated hereby (collectively, the "Client"), to act as the Client's advisor in connection with a possible Financing (as defined below) and the Client's use of MSC's proprietary technology platform (the “MSC Platform").
EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • December 29th, 2021 • Global Cancer Technology, Inc. • Surgical & medical instruments & apparatus • California
This EXCLUSIVE LICENSE AGREEMENT (this "Agreement") is made as of the First day of September, 2020 ("Effective Date"), by and between Neuropore Therapies, Inc., a corporation organized under the laws of the State of Delaware, having its principal office at 10835 Road to the Cure, Suite 230, San Diego, CA 92121 (the "Licensor"), and Global Cancer Technology, Inc., a corporation organized under the laws of the State of Nevada having its principal office at 16776 Bernardo Center Drive, Suite 203, San Diego, CA 92128 (the "Licensee" and together with the Licensor the "Parties" and each a "Party").
EXCLUSIVE START-UP LICENSE AGREEMENT BETWEEN GLOBAL CANCER TECHNOLOGY AND UNIVERSITY OF WASHINGTON FOR BOILING HISTOTRIPSY UW COMOTION AGREEMENT 42157AExclusive Start-Up License Agreement • October 15th, 2018 • Global Cancer Technology, Inc. • Surgical & medical instruments & apparatus • Washington
This Exclusive License Agreement (this “Agreement”), effective as of March 8, 2018 (the “Effective Date”), is made and entered into between the University of Washington, a public institution of higher education and an agency of the state of Washington, (“University”), and Global Cancer Technology, a corporation in the state of Nevada (“Company”).
NanoMed Tracking Inc. Shareholder AgreementShareholder Agreement • October 15th, 2018 • Global Cancer Technology, Inc. • Surgical & medical instruments & apparatus
This agreement, made and entered into as of the 7th day of June 26th, 2017 by and among Global Cancer Technology, Inc., whose address is: 16776 Bernardo Center Drive # 203 San Diego, CA 92128 (hereinafter referred to as "GCT"), and Milan Makale, Wolf Wrasidio, Sadik Esner and Thomas Hamelin, (collectively called ‘Founding Partners’) and utilizing the common address of: The John Moores Cancer Center, 3855 Health Sciences Drive, La Jolla, CA 92037. Together GCT and the Founding Partners come together to form NanoMed Tracking, Inc. ("the Corporation"), which will be filed in the State of Nevada.
GLOBAL CANCER TECHNOLOGY, INC. Subscription AgreementSubscription Agreement • October 15th, 2018 • Global Cancer Technology, Inc. • Surgical & medical instruments & apparatus • Nevada
LICENSE AGREEMENTLicense Agreement • October 15th, 2018 • Global Cancer Technology, Inc. • Surgical & medical instruments & apparatus • California
This agreement ("Agreement") is entered into as of the date of last signature below, (the "Effective Date") by and between Global Cancer Technology, Inc., a Nevada corporation, having an address at 16776 Bernardo Center Dr., Suite 203, San Diego, CA 92128 ("LICENSEE") and The Regents of the University of California, a California public corporation having its statewide administrative offices at 1111 Franklin Street, Oakland, California 94607-5200 ("UNIVERSITY"), represented by its San Diego campus having an address at University of California, San Diego, Office of Innovation and Commercialization, Mail Code 0910, 9500 Gilman Drive, La Jolla, California 92093-0910 ("UCSD").
American Radiosurgery, Inc & Global Cancer Technology, Inc Technology License Agreement Prepared: October 1, 2017 Private and ConfidentialTechnology License Agreement • October 15th, 2018 • Global Cancer Technology, Inc. • Surgical & medical instruments & apparatus • California
This Agreement shall commence on the signing of this agreement by both parties and provided that the Licensee conforms to all conditions, obligations, and duties, as set forth herein, and in the Exhibits. the Licensee’s performance shall meet or exceed the sales quota(s) as outlined in Exhibit “F” (attached) all of which are made a part of this Agreement.
AMENDMENT NO. 2 TO LICENSE AGREEMENT NO. 2017-03-0236 (THE “AGREEMENT”) BETWEEN GLOBAL CANCER TECHNOLOGY, INC. AND THE UNIVERSITY OF CALIFORNIA FOR CASE NOS. SD2013-199 AND SD2020-395 (SD2016-342 EXCLUDED STARTING AMENDMENT #2 DATE)License Agreement • July 13th, 2021 • Global Cancer Technology, Inc. • Surgical & medical instruments & apparatus
This amendment (“Amendment #2”) is made by and between Global Cancer Technology, Inc. a Nevada corporation, having an address at 16776 Bernardo Center Dr., Suite 203, San Diego, CA 92128 (“LICENSEE”), and The Regents Of The University Of California, a California corporation having its statewide administrative offices at 1111 Franklin Street, Oakland, California 94607-5200 (“UNIVERSITY”), as represented by its San Diego campus having an address at University of California, San Diego, Office of Innovation and Commercialization, Mail Code 0910, 9500 Gilman Drive, La Jolla, California 92093-0910 (“UCSD”).
EMPLOYMENT AGREEMENTEmployment Agreement • September 7th, 2018 • Global Cancer Technology, Inc. • Surgical & medical instruments & apparatus • California
This EMPLOYMENT AGREEMENT (the “Agreement”) entered into this 1st day of May 2018 (the “Effective Date”), is by and between Global Cancer Technology, Inc., a corporation formed under the laws of the State of Arizona (the “Employer”), and John P Clark (the “Employee”).
MCW PHARMACEUTICALS, INC (a subsidiary of Global Cancer Technology in formation) Shareholder AgreementShareholder Agreement • October 15th, 2018 • Global Cancer Technology, Inc. • Surgical & medical instruments & apparatus
This agreement, made and entered into as of May 17th, 2018 by and among Global Cancer Technology, Inc., whose address is: 16776 Bernardo Center Drive # 203 San Diego, CA 92128 (hereinafter referred to as "GCT"), and Milan Makale and Wolf Wrasidio, (collectively called ‘Founding Partners’) and utilizing the common address of: The John Moores Cancer Center, 3855 Health Sciences Drive, La Jolla, CA 92037. Together GCT and the Founding Partners come together to form MCW PHARMACEUTICALS, Inc. ("the Corporation"), which will be filed in the State of Montana.
AMENDMENT NO. 1 TO LICENSE AGREEMENT NO. 2017-03-0236 (THE “AGREEMENT”) BETWEEN GLOBAL CANCER TECHNOLOGY, INC. AND THE UNIVERSITY OF CALIFORNIA FOR CASE NOS. SD2013-199, SD2016-342, AND UPON AMENDMENT, SD2020-395License Agreement • September 3rd, 2020 • Global Cancer Technology, Inc. • Surgical & medical instruments & apparatus
This amendment (“Amendment #1”) is made by and between Global Cancer Technology, Inc. a Nevada corporation, having an address at 16776 Bernardo Center Dr., Suite 203, San Diego, CA 92128 (“LICENSEE”), and The Regents Of The University Of California, a California corporation having its statewide administrative offices at 1111 Franklin Street, Oakland, California 94607-5200 (“UNIVERSITY”), as represented by its San Diego campus having an address at University of California, San Diego, Office of Innovation and Commercialization, Mail Code 0910, 9500 Gilman Drive, La Jolla, California 92093-0910 (“UCSD”).
SPONSORED RESEARCH AGREEMENT between The University of Washington and Global Cancer TechnologySponsored Research Agreement • September 7th, 2018 • Global Cancer Technology, Inc. • Surgical & medical instruments & apparatus • Washington
This Sponsored Research Agreement (“Agreement”) is entered into as of August 21st, 2018, (“Effective Date”) between the University of Washington, an institution of higher education and an agency of the State of Washington having its principal campus located at 4333 Brooklyn Ave NE Seattle, Washington 98195 (“UW”), and Global Cancer Technology, Inc, a for-profit corporation organized under the laws of the State of Nevada having its principal place of business located at Global Cancer Technology, Inc 16776 Bernardo Center Dr.#203 San Diego, CA 92128
LICENSE AGREEMENTLicense Agreement • October 15th, 2018 • Global Cancer Technology, Inc. • Surgical & medical instruments & apparatus • California
This agreement ("Agreement") is entered into as of the date of last signature below, (the "Effective Date") by and between Global Cancer Technology, Inc., a Nevada corporation, having an address at 16776 Bernardo Center Dr., Suite 203, San Diego, CA 92128 ("LICENSEE") and The Regents of the University of California, a California public corporation having its statewide administrative offices at 1111 Franklin Street, Oakland, California 94607-5200 ("UNIVERSITY"), represented by its San Diego campus having an address at University of California, San Diego, Office of Innovation and Commercialization, Mail Code 0910, 9500 Gilman Drive, La Jolla, California 92093-0910 ("UCSD").
